Cargando…
Estimation of the in vivo neutralization potency of eCD4Ig and conditions for AAV-mediated production for SHIV long-term remission
The engineered protein eCD4Ig has emerged as a promising approach to achieve HIV remission in the absence of antiviral therapy. eCD4Ig neutralizes nearly all HIV-1 isolates and induces antibody-dependent cell-mediated cytotoxicity (ADCC) in vitro. To characterize the in vivo antiviral neutralization...
Autores principales: | Goyal, Ashish, Gardner, Matthew, Mayer, Bryan T., Jerome, Keith R., Farzan, Michael, Schiffer, Joshua T., Cardozo-Ojeda, E. Fabian |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
American Association for the Advancement of Science
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8754410/ https://www.ncbi.nlm.nih.gov/pubmed/35020436 http://dx.doi.org/10.1126/sciadv.abj5666 |
Ejemplares similares
-
AAV-expressed eCD4-Ig provides durable protection from multiple SHIV challenges
por: Gardner, Matthew R., et al.
Publicado: (2015) -
Semirational bioengineering of AAV vectors with increased potency and specificity for systemic gene therapy of muscle disorders
por: El Andari, Jihad, et al.
Publicado: (2022) -
Potency and timing of antiviral therapy as determinants of duration of SARS-CoV-2 shedding and intensity of inflammatory response
por: Goyal, Ashish, et al.
Publicado: (2020) -
TWIST1 and TSG6 are coordinately regulated and function as potency biomarkers in human MSCs
por: Lee, Ryang Hwa, et al.
Publicado: (2023) -
Targeting oxidized phospholipids by AAV-based gene therapy in mice with established hepatic steatosis prevents progression to fibrosis
por: Upchurch, Clint M., et al.
Publicado: (2022)